CL2012000042A1 - Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto. - Google Patents
Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto.Info
- Publication number
- CL2012000042A1 CL2012000042A1 CL2012000042A CL2012000042A CL2012000042A1 CL 2012000042 A1 CL2012000042 A1 CL 2012000042A1 CL 2012000042 A CL2012000042 A CL 2012000042A CL 2012000042 A CL2012000042 A CL 2012000042A CL 2012000042 A1 CL2012000042 A1 CL 2012000042A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- alkylocl
- alkyl
- hydrogen
- imidazo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- -1 imidazo [1,2-a] pyrazin-7-yl Chemical group 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000224016 Plasmodium Species 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001721 carbon Chemical class 0.000 abstract 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPUESTOS DERIVADOS DE IMIDAZO[1 ,2-AJPIRAZIN-7-II REPRESENTADO POR LA FORMULA LA: EN DONDE RA SE SELECCIONA A PARTIR DE -X3NR7R8, -X30R8, -X35(0)0-2R8, -X3C(0)NR7R8 Y BENCILO OPCIONA!MENTE SUSTITUIDO COMO SE DESCRIBE EN LAS REIVINDICACIONES; R2 SE SELECCIONA ENTRE HIDRÓGENO, ALQUILOCL-6, AMINO, CICLOALQUILC3-8-ALQUILOCO-4, ARIL-C6-10-ALQUILOCO-4, ALQUILOCL -6 HALO-SUSTITUIDO, ALQUILOCL -6 HIDROXI-SUSTITUIDO Y HETEROCICLIL-ALQUILOCO-4; DEFINIDO EN LAS REIVINDICACIONES; EN DONDE DICHO ARILOC6-1 O O HETEROCICLO DE R2 ESTÁ OPCIONALMENTE SUSTITUIDO; O R2 Y R3 JUNTO CON EL ÁTOMO DE CARBONO AL CUAL R2 Y R3 ESTÁN UNIDOS FORMAN UN CICLOALQUILOC3-8; O R2 Y R13 JUNTO CON LOS ÁTOMOS A LOS CUALES P2 Y R13 ESTÁN UNIDOS FORMAN UN ANILLO HETEROCÍCLICO MONO O FUSIONADO COMO SE DEFINE EN LAS REIVINDICACIONES; R4 Y R5 SE SELECCIONA ENTRE HIDRÓGENO Y ALQUILOCL-6; O P4 Y RS JUNTO CON EL ÁTOMO DE CARBONO AL CUAL R4 Y P5 ESTÁN UNIDOS FORMAN UN CICLOALQUILOC3-8; P6 SE SELECCIONA ENTRE ARILOC6-10, CICLOALQUILOC3-8 Y UN ANILLO HETEROCÍCLICO MONO O FUSIONADO DEFINIDO EN LAS REIVINDICACIONES; R9, RIO, Y RL 1, SE SELECCIONA ENTRE HIDRÓGENO Y ALQUILO CI-6; R12 SE SELECCIONA ENTRE HIDRÓGENO Y ALQUILO C1-6; O RL 1 Y R12 COMBINADOS PARA FORMAR UN C(0); O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EL RESTO DE LOS RADICALES SE DEFINEN COMO EN EL CAPÍTULO REIVINDICATORIO. ADICIONALMENTE, LA INVENCIÓN RECLAMA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS Y USOS PARA TRATAR O PREVENIR EL PALUDISMO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22443309P | 2009-07-09 | 2009-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000042A1 true CL2012000042A1 (es) | 2012-12-21 |
Family
ID=42727573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000042A CL2012000042A1 (es) | 2009-07-09 | 2012-01-06 | Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto. |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US8557801B2 (es) |
| EP (2) | EP2451814B1 (es) |
| JP (1) | JP5432376B2 (es) |
| KR (1) | KR101378666B1 (es) |
| CN (1) | CN102471341B (es) |
| AR (1) | AR077463A1 (es) |
| AU (1) | AU2010271247B2 (es) |
| BR (1) | BR112012000413B1 (es) |
| CA (1) | CA2767664C (es) |
| CL (1) | CL2012000042A1 (es) |
| CO (1) | CO6491060A2 (es) |
| CR (1) | CR20120008A (es) |
| CU (1) | CU24155B1 (es) |
| DK (1) | DK2451814T3 (es) |
| EA (1) | EA019655B1 (es) |
| EC (1) | ECSP12011585A (es) |
| ES (2) | ES2574529T3 (es) |
| GT (1) | GT201200004A (es) |
| HK (1) | HK1164304A1 (es) |
| HN (1) | HN2012000023A (es) |
| HR (1) | HRP20140641T1 (es) |
| IL (1) | IL217384A (es) |
| JO (1) | JO3156B1 (es) |
| MA (1) | MA33419B1 (es) |
| MX (1) | MX2012000389A (es) |
| MY (1) | MY157238A (es) |
| NZ (1) | NZ597275A (es) |
| PE (1) | PE20130399A1 (es) |
| PL (1) | PL2451814T3 (es) |
| PT (1) | PT2451814E (es) |
| SG (1) | SG176938A1 (es) |
| SI (1) | SI2451814T1 (es) |
| SM (1) | SMT201400096B (es) |
| TN (1) | TN2011000647A1 (es) |
| TW (1) | TWI421252B (es) |
| UA (1) | UA103930C2 (es) |
| UY (1) | UY32776A (es) |
| WO (1) | WO2011006143A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2920169A1 (en) * | 2012-11-14 | 2015-09-23 | F. Hoffmann-La Roche AG | Imidazopyridine derivatives |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| CN105189506A (zh) * | 2012-11-19 | 2015-12-23 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
| PL2925757T3 (pl) * | 2012-11-19 | 2018-06-29 | Novartis Ag | Związki i kompozycje do leczenia chorób pasożytniczych |
| CN103126782B (zh) * | 2013-02-26 | 2016-06-29 | 内蒙古农牧业科学院 | 一种寄生病的治疗方法 |
| WO2015095477A1 (en) * | 2013-12-19 | 2015-06-25 | Irm Llc | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis |
| EP3328857B1 (en) | 2015-07-31 | 2019-08-14 | Merck Patent GmbH | Bicyclic heterocyclic derivatives |
| US10660334B2 (en) * | 2016-08-15 | 2020-05-26 | Bayer Cropscience Aktiengesellschaft | Fused bicyclic heterocycle derivatives as pesticides |
| AU2018260414A1 (en) * | 2017-04-24 | 2019-10-17 | Novartis Ag | Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof |
| KR102664604B1 (ko) | 2017-07-14 | 2024-05-14 | 에프. 호프만-라 로슈 아게 | 이환형 케톤 화합물 및 이의 사용 방법 |
| WO2022049548A1 (en) | 2020-09-04 | 2022-03-10 | Novartis Ag | Kaf156 combinations and methods for the treatment of malaria |
| WO2023168107A2 (en) * | 2022-03-04 | 2023-09-07 | University Of Central Florida Research Foundation, Inc. | Compounds and compositions for anitmalarial therapeutic and prophylactic use |
| CN114569711B (zh) * | 2022-03-24 | 2024-04-19 | 安徽医科大学 | 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用 |
| WO2024006974A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
| WO2024006971A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
| WO2024006970A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK476885D0 (da) | 1985-10-17 | 1985-10-17 | Ferrosan As | Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf |
| US6673927B2 (en) | 1996-02-16 | 2004-01-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Farnesyl transferase inhibitors |
| ATE279396T1 (de) | 1998-06-12 | 2004-10-15 | Sod Conseils Rech Applic | Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden |
| FR2780974B1 (fr) | 1998-07-08 | 2001-09-28 | Sod Conseils Rech Applic | Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique |
| DE69915514T2 (de) | 1998-12-31 | 2005-01-05 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Prenyltransferase-inhibitoren |
| CA2390317C (fr) | 1999-11-09 | 2010-03-23 | Gregoire Prevost | Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
| FR2803525B1 (fr) | 2000-01-06 | 2002-05-03 | Sod Conseils Rech Applic | Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle |
| ATE360620T1 (de) | 2000-08-01 | 2007-05-15 | Sod Conseils Rech Applic | Imidazolderivate |
| ATE295362T1 (de) * | 2001-01-02 | 2005-05-15 | Hoffmann La Roche | Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten |
| FR2825278A1 (fr) | 2001-05-30 | 2002-12-06 | Sod Conseils Rech Applic | Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
| UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| CA2478389A1 (en) | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US20060166907A1 (en) | 2002-09-27 | 2006-07-27 | Gregoire Prevost | Composition for the treatment of nasopharyngeal carcinoma and method of use thereof |
| CA2508947A1 (en) * | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| BR0317430A (pt) | 2002-12-20 | 2005-10-25 | Pharmacia Corp | Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno |
| JP2006520819A (ja) * | 2003-03-06 | 2006-09-14 | メルク エンド カムパニー インコーポレーテッド | 抗原虫薬イミダゾピリジン化合物 |
| AR043633A1 (es) * | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
| CN1787823A (zh) | 2003-05-14 | 2006-06-14 | 麦克公司 | 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的3－氨基－4－苯基丁酸衍生物 |
| FR2856688B1 (fr) | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| FR2867778B1 (fr) * | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
| KR20080030652A (ko) | 2005-08-11 | 2008-04-04 | 에프. 호프만-라 로슈 아게 | Ｄｐｐ-ｉｖ 억제제를 포함하는 약학 조성물 |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| WO2007124423A2 (en) | 2006-04-21 | 2007-11-01 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| US20120142623A1 (en) | 2006-07-07 | 2012-06-07 | Michael Lagunoff | Compositions And Methods For Predicting Inhibitors Of Protein Targets |
| TW200808056A (en) * | 2006-07-26 | 2008-02-01 | Compal Communications Inc | Rear projection display system |
| AU2008210904A1 (en) * | 2007-01-26 | 2008-08-07 | Irm Llc | Purine compounds and compositions as kinase inhibitors for the treatment of Plasmodium related diseases |
| US20080242862A1 (en) * | 2007-03-27 | 2008-10-02 | Calderwood David J | Novel imidazo based heterocycles |
| EP2170337A4 (en) | 2007-06-28 | 2013-12-18 | Abbvie Inc | NEW TRIAZOLOPYRIDAZINE |
| CN101357922B (zh) | 2007-08-02 | 2011-05-18 | 山东轩竹医药科技有限公司 | 新的dpp-iv抑制剂 |
| EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| EP2300466B1 (en) | 2008-06-20 | 2014-08-06 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
-
2010
- 2010-07-08 JO JOP/2010/0245A patent/JO3156B1/ar active
- 2010-07-08 AR ARP100102479A patent/AR077463A1/es active IP Right Grant
- 2010-07-08 UY UY0001032776A patent/UY32776A/es active IP Right Grant
- 2010-07-08 TW TW099122545A patent/TWI421252B/zh active
- 2010-07-09 CN CN201080029052.1A patent/CN102471341B/zh active Active
- 2010-07-09 JP JP2012519791A patent/JP5432376B2/ja active Active
- 2010-07-09 ES ES14156496.3T patent/ES2574529T3/es active Active
- 2010-07-09 SG SG2011094612A patent/SG176938A1/en unknown
- 2010-07-09 EP EP10733107.6A patent/EP2451814B1/en active Active
- 2010-07-09 NZ NZ597275A patent/NZ597275A/xx unknown
- 2010-07-09 EP EP14156496.3A patent/EP2737927B1/en active Active
- 2010-07-09 PT PT107331076T patent/PT2451814E/pt unknown
- 2010-07-09 WO PCT/US2010/041626 patent/WO2011006143A2/en active Application Filing
- 2010-07-09 MX MX2012000389A patent/MX2012000389A/es active IP Right Grant
- 2010-07-09 BR BR112012000413-1A patent/BR112012000413B1/pt active IP Right Grant
- 2010-07-09 DK DK10733107.6T patent/DK2451814T3/da active
- 2010-07-09 KR KR1020127003375A patent/KR101378666B1/ko active IP Right Grant
- 2010-07-09 CA CA2767664A patent/CA2767664C/en active Active
- 2010-07-09 UA UAA201200238A patent/UA103930C2/ru unknown
- 2010-07-09 CU CU20120002A patent/CU24155B1/es active IP Right Grant
- 2010-07-09 MA MA34520A patent/MA33419B1/fr unknown
- 2010-07-09 AU AU2010271247A patent/AU2010271247B2/en active Active
- 2010-07-09 EA EA201200098A patent/EA019655B1/ru not_active IP Right Cessation
- 2010-07-09 MY MYPI2011006324A patent/MY157238A/en unknown
- 2010-07-09 US US12/833,909 patent/US8557801B2/en active Active
- 2010-07-09 PL PL10733107T patent/PL2451814T3/pl unknown
- 2010-07-09 PE PE2012000026A patent/PE20130399A1/es active IP Right Grant
- 2010-07-09 ES ES10733107.6T patent/ES2477940T3/es active Active
- 2010-07-09 SI SI201030656T patent/SI2451814T1/sl unknown
-
2011
- 2011-12-16 TN TNP2011000647A patent/TN2011000647A1/en unknown
-
2012
- 2012-01-05 HN HN2012000023A patent/HN2012000023A/es unknown
- 2012-01-05 IL IL217384A patent/IL217384A/en active IP Right Grant
- 2012-01-06 CL CL2012000042A patent/CL2012000042A1/es unknown
- 2012-01-06 GT GT201200004A patent/GT201200004A/es unknown
- 2012-01-09 EC EC2012011585A patent/ECSP12011585A/es unknown
- 2012-01-09 CR CR20120008A patent/CR20120008A/es unknown
- 2012-01-19 CO CO12007883A patent/CO6491060A2/es active IP Right Grant
- 2012-05-17 HK HK12104874.9A patent/HK1164304A1/xx unknown
-
2013
- 2013-06-07 US US13/912,898 patent/US9469645B2/en active Active
-
2014
- 2014-07-07 HR HRP20140641AT patent/HRP20140641T1/hr unknown
- 2014-07-22 SM SM201400096T patent/SMT201400096B/xx unknown
-
2015
- 2015-12-22 US US14/978,059 patent/US9963454B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012000042A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto. | |
| CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| BR112013007696A2 (pt) | composto, composição farmacêutica, usos do referido composto e da referida composição | |
| CU20110145A7 (es) | Derivados de sulfonamida | |
| DOP2014000303A (es) | 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| CR20110616A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| AR093532A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| UY29469A1 (es) | Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos. | |
| DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
| CL2011001924A1 (es) | Compuestos derivados de aminotetralina, inhibidores de glyt1; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso en el tratamiento de problemas neurologicos, psiquiatricos o dolor. | |
| UY29301A1 (es) | Derivados amida | |
| UY31730A (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica. | |
| EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
| CR20120237A (es) | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| UY28578A1 (es) | Derivados de amida | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| AR085039A1 (es) | DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR | |
| UY30438A1 (es) | Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos | |
| DOP2009000254A (es) | Derivados de piridina | |
| UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones |